SNSS - Sunesis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
237
669
2,536
3,061
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
3,061
Operating Expenses
Research Development
13,766
14,615
21,540
22,881
23,701
Selling General and Administrative
9,928
11,332
13,548
16,115
18,662
Total Operating Expenses
23,694
25,947
35,088
38,996
42,363
Operating Income or Loss
-23,694
-25,710
-34,419
-36,460
-39,302
Interest Expense
738
1,154
1,396
1,721
939
Total Other Income/Expenses Net
392
249
357
158
3,565
Income Before Tax
-24,040
-26,615
-35,458
-38,023
-36,676
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-24,040
-26,615
-35,458
-38,023
-36,676
Net Income
-24,040
-26,615
-35,458
-38,023
-36,676
Net Income available to common shareholders
-24,040
-26,615
-35,458
-38,023
-36,676
Reported EPS
Basic
-
-0.75
-1.45
-2.42
-3.00
Diluted
-
-0.75
-1.45
-2.42
-3.00
Weighted average shares outstanding
Basic
-
35,582
24,516
15,688
12,156
Diluted
-
35,582
24,516
15,688
12,156
EBITDA
-
-25,452
-34,053
-36,291
-35,737